Assenagon Asset Management S.A. Has $268.66 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Assenagon Asset Management S.A. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 477,810 shares of the biopharmaceutical company’s stock after buying an additional 54,485 shares during the period. Assenagon Asset Management S.A.’s holdings in Regeneron Pharmaceuticals were worth $268,658,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after acquiring an additional 42,343 shares in the last quarter. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Regeneron Pharmaceuticals by 1.6% in the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after purchasing an additional 36,821 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after purchasing an additional 89,579 shares during the period. Finally, Loomis Sayles & Co. L P lifted its stake in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.8%

REGN opened at $746.36 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $790.98. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The firm’s fifty day moving average price is $671.04 and its two-hundred day moving average price is $595.57. The company has a market capitalization of $78.44 billion, a P/E ratio of 17.87, a P/E/G ratio of 2.15 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.46 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. Bank of America lifted their target price on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Scotiabank lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $779.45.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.